Vyant Bio, Inc. (Vyant Bio) is a biotechnology drug discovery company focused on identifying unique biological targets and novel and repurposed therapeutics. Vyant Bio is also focused on combining sophisticated data science capabilities with highly functional human cell derived disease models. Vyant Bio’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. The Company’s platform is designed to elucidate disease pathophysiology; formulate key therapeutic hypotheses; identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection, and guide clinical trial patient selection and trial design. Vyant Bio’s programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 Deficiency Disorders (CDD) and familial Parkinsons Disease (PD).